Genes encoding the rearranged immunoglobulin heavy and light chain variable regions of DO-1, a monoclonal antibody directed against human p53, have been used to construct a single-chain antibody. DO-1 recognizes an N-terminal epitope in the region involved in the transactivation function of p53 and the binding of Mdm2. The DO-1 single chain scFv expressed in the periplasm of E. coli or at the surface of the ®lamentous phage M13 retained the immunological speci®city and anity of the full length antibody. Furthermore, the DO-1 recombinant antibody was able to inhibit the in vitro binding of Hdm2, and was shown to be a powerful protecting agent of p53's DNA binding activity at 378C. The DO-1 single-chain antibody has been used to construct single-chain intracellular antibodies (intrabodies) for expression in the cytoplasm and the nucleus of mammalian cells. These anti-p53 intrabodies were additionally modi®ed by addition of a Ck domain to increase cytoplasmic and nuclear stability. Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in an inhibition of p53's transactivation function. The DO-1 intrabody is a useful tool to study those functions of p53 driven by the Nterminal region of the protein.
Introduction
The p53 tumour suppressor has become the centre of extensive studies since it has been found to be inactivated, either by missense mutation or interaction with oncogenic or viral proteins, in more than half of all human cancers. The p53 protein suppresses oncogenic transformation (Eliyahu et al., 1984; Finlay et al., 1989) and induces cell cycle arrest (Leonardo et al., 1994) or programmed cell death (Clarke et al., 1993) . p53 acts as a sequence-speci®c transcription factor that activates a number of genes implicated, at least in part, in p53-dependent functions. These include gadd45 (Kastan et al., 1992) , mdm2 (Barak et al., 1993) , p21 (waf1/cip1) (El Deiry et al., 1993) , cyclin G (Okamoto and Beach, 1994) , IGF-BP3 (Buckbinder et al., 1995) , bax (Miyashita and Reed, 1995) and PIG3 (Polyak et al., 1997) . p53 can also act as a transcriptional repressor, and down-regulate promoters lacking wild-type p53 binding sites (Subler et al., 1992) .
The amino-terminal region of p53 is acidic and proline-rich, and holds the transcriptional transactivation function of the protein (Fields and Jang, 1990; Raycroft et al., 1990) . This region has been shown to interact with the components of the basal transcriptional machinery TATA-binding proteins (TBP) (Seto et al., 1992) , the TBP associated coactivator factors TAFII40, TAFII60 (Thut et al., 1995) , TAFII31 (Lu and Levine, 1995) and members of the transcriptional coactivators p300/CBP family (Gu et al., 1997; Lill et al., 1997) . The transactivation domain of p53 has been mapped to residues 1 ± 40 of the N-terminal region of the protein (Unger et al., 1992) , and recently, a second independent activation domain of p53 has been identi®ed, and localized to the amino acid 40 ± 83 region (Candau et al., 1997 ). p53's transactivation function is negatively regulated by proteins interacting with the N-terminal region, in particular by the E1B-55 kDa protein from adenovirus type 5 (Braithwaite and Jenkins, 1989 ) and the oncogenic Mdm2 protein Chen et al., 1993; Oliner et al., 1993) . Mutational analysis has demonstrated that residues L22 and W23 of the human p53 sequence play a key role in the transcriptional activity of p53, and are crucial for the binding of E1B, Mdm2, TAFs proteins, and CBP protein (Lin et al., 1994; Thut et al., 1995; Lu and Levine, 1995; Gu et al., 1997) . This suggests that inhibition of p53's transcriptional activity by Mdm2 is probably achieved by concealing the transactivation domain of p53 (Chen et al., 1993; Oliner et al., 1993) . The Mdm2 (murine double minute gene 2) protein (Cahilly-Snyder et al., 1987) is tumorigenic when overexpressed in nude mice (Fakharzadeh et al., 1991) , and the Mdm2 human homolog (Hdm2) is found to be overexpressed in human sarcomas where the p53 gene remains wild type (Oliner et al., 1992) . Much eort has been devoted to the molecular characterization of the Mdm2-p53 interaction. Using synthetic (Picksley et al., 1994) or phage-displayed (Bottger et al., 1996) peptides, the Hdm2-binding site on human p53 has been identi®ed as the 18TFSDLWKLL26 sequence. A co-crystalization study (Kussie et al., 1996) shows that the Nterminus of p53 forms an amphipathic a helix bound into a deep hydrophobic pocket on the Mdm2 molecule, and that residues F19, W23 and L26 of p53 are particularly involved in the interaction.
In addition to the transactivation function, the Nterminal region of p53 seems to be involved in the regulation of the rate of turnover of the protein. For instance, deletion of the residues 13-19 results in a mutant protein more stable than wild-type p53 (Marston et al., 1994) . Other studies suggest that calpain is involved in the degradation pathway of p53 in the cell system Pariat et al., 1997) , and that the site of cleavage of calpain on the p53 molecule is localized in vitro in the 20-25 Nterminal region . Ubiquitin-dependent proteolysis is one of the mechanisms by which p53 might be degraded (Maki et al., 1996) ; although factors governing recognition by the ubiquitin system are not very well understood, there is evidence that residues at the N-terminus of proteins play a role (Varhavsky, 1992) . Ubiquitin-dependent proteolysis of p53 has been shown to be promoted by the E6 protein from human papillomavirus (Schener et al., 1990) and by Mdm2 (Haupt et al., 1997; . Interestingly, other proteins belonging to the Mdm2 family have been found to bind to p53 in a similar manner as Mdm2 (Shvarts et al., 1996) , opening the way for a new class of endogenous proteins modulating p53's functions via the N-terminus.
Post-translational events such as reversible phosphorylation may also regulate p53's activities. Threonine or serine residues within the N-terminal region are targets for phosphorylation by various kinases: CK I (Milne et al., 1992) , raf kinase (Jamal and Zi, 1995) , MAP kinase (Milne et al., 1994) , and DNA-PK (Lees Miller et al., 1992; Wang and Eckhart, 1992) . The DNA-dependent kinase which phosphorylates S15 and S37 of human p53 is an interesting candidate, as it has been shown that mutation on S15 modulates the protein's activities and stability (Fiscella et al., 1993) , and that phosphorylation of S15 and S37 impairs the ability of Mdm2 to inhibit p53-dependent transactivation (Shieh et al., 1997 ). p53's interaction with Mdm2 may also be aected by modi®cation of Mdm2 itself by the DNA-dependent kinase (Mayo et al., 1997) .
In order to study the regulation of p53's activities involving the N-terminal region of the protein, we decided to use an innovative approach based on the intracellular expression of recombinant antibodies. Intracellular antibodies (intrabodies) represent one of the most recent advances in antibody engineering (for review : Marasco, 1995) . They are synthesized by the cell and targeted to a speci®c cellular compartment in order to manipulate the function of the antigen of interest. With this in mind, we decided to engineer a recombinant antibody fragment (single chain fragment variable or scFv) of the DO-1 monoclonal antibody (Vojtesek et al., 1992) . DO-1 antibody binds to human p53 at a N-terminal linear epitope 20SDLWKL25 (Stephen et al., 1995) which overlaps with the Hdm2 binding site (Picksley et al., 1994; Bottger et al., 1997) and the calpain cleavage site .
In our study, we describe the in vitro characterization of DO-1 scFv after expression in E. coli as a soluble molecule or at the surface of the ®lamentous phage M13. Interaction between human p53 and puri®ed scFv from the periplasmic fraction of E. coli was investigated by enzyme linked immunosorbent assays and electrophoretic mobility shift assays. Dierent constructs have been designed to allow stable expression of the scFv in the nucleus or the cytoplasm of mammalian cells. In this study we show that the intracellularly expressed scFv is functional as it results in an inhibition of p53's transactivation function.
Results
Engineering of the DO-1 single chain fragment variable (scFv) Dierent strategies have been described to produce and construct a scFv from a hybridoma cell line. The most common method involves separately amplifying the variable domains of both the heavy (VH) and light (VL) chains of immunoglobulin (Ig), utilizing a set of oligonucleotides which anneal to the 5' and 3' ends of the majority of the V region gene families. The DNA fragments of the two variable regions are then assembled into a single gene using a DNA linker fragment encoding the (Gly4Ser)3 sequence. This approach was unsuccessful for construction of the DO-1 scFv, because the VH DNA fragment could not be ampli®ed. We decided to use an alternative strategy, through the construction of a cDNA library from the DO-1 hybridoma cell line. The library was screened for the DO-1 heavy (IgG2a) and light (k) chains, using two oligonucleotide probes which anneal, respectively, on the ®rst constant region of IgG2a mouse heavy chain or on the constant region of mouse kappa light chains. Several positive clones were sequenced and primers were designed to construct, by overlap-extension PCR, the DO-1 scFv (see Material and methods). Sequence comparison using data from the Immunogenetics Database (DNA plot), showed that the VH region of the DO-1 antibody belongs to the mouse VH8 family. The third hypervariable complementary-determining region (CDR3) is composed of the DQ52 gene and the JH2 gene. The VL region belongs to the mouse Vk1 group II subgroup and uses the JK5 gene.
E. coli expressed DO-1 scFv keeps the same speci®city and the same anity as the DO-1 monoclonal antibody
To determine the binding activity of the engineered antibody fragment, the DO-1 scFv was cloned into the prokaryotic phagemid expression vector pCANTAB 5E. This vector displays the expressed scFv on the surface of the ®lamentous M13 phage by fusion with the gene III minor coat protein (g3p) that is required for host infection (McCaerty et al., 1990) . Following isopropyl-thiogalactoside (IPTG) induction, soluble scFv can also be expressed in the periplasmic space of amber-suppressor bacteria (HB2151 E. coli strain) recognizing an amber mutation interposed between genes encoding the antibody fragment and the coat protein (Hoogenboom et al., 1991) . To allow the immunodetection of the soluble scFv, the E-tag peptide was fused in frame at the C-terminus of the Vk domain ( Figure 1a) . Preparation of pure DO-1 scFv from E. coli periplasm was achieved by immunoanity puri®cation using the anti-E-tag antibody immobilized onto a N-hydroxysuccinimide activated Sepharose column (Pharmacia, Uppsala, Sweden). Analysis by SDS ± PAGE (silver staining) revealed a band at the expected size (30 kDa), with a purity greater than 95% (data not shown). The average yield of immunopuri®cation from the periplasmic fractions was 100 ± 120 mg of scFv per liter of bacterial culture.
Phage-displayed or soluble DO-1 scFv were tested for binding to human p53 by an enzyme linked immunosorbent assay (ELISA). As shown on Figure  2a , the soluble DO-1 scFv puri®ed from E. coli periplasm is able to recognize recombinant human p53 expressed in dierent systems: E. coli, insect cells, or human p53 null tumour cell line H1299. This result was con®rmed for the phage-displayed scFv (data not shown). The DO-1 epitope has been mapped by Stephen and colleagues (1995) as the 20SDLWKL25 sequence. Fine speci®city of the DO-1 scFv has been investigated by testing the recognition of biotinylated peptides containing the human DO-1 epitope and the corresponding region of murine p53. Figure 2b shows that the recombinant antibody fragment expressed at the surface of the M13 phage retains the same speci®city as the DO-1 parental antibody; that is that it is able to recognize human but not murine p53. This was also con®rmed with the soluble DO-1 scFv (data not shown).
In order to test the recognition of human p53 in another format, we performed an electrophoretic mobility shift assay (EMSA) in which insect cellproduced recombinant human p53 speci®cally binds to DNA as a tetrameric complex (Hupp and Lane, 1994) . A titration of DO-1 parental antibody gave rise to an intermediate form of the p53/DNA complex ( Figure 3 , lanes 9 ± 15), corresponding to two DO-1 Ig molecules bound per tetrameric p53, suggesting that at least two DO-1 epitopes are accessible on the tetrameric form of p53 (Hupp et al., 1992) . When the assay is performed in the presence of the scFv, the p53/DNA band is supershifted, demonstrating that recombinant antibody is able to recognize the p53/DNA complex. A titration of DO-1 scFv leads to the formation of three intermediate complexes ( Figure 3 , lanes 2 ± 7), demonstrating that all four N-terminal DO-1 epitopes are accessible on the tetrameric form of p53.
Finally, we characterized the kinetic rates of the DO-1/p53 interaction by surface plasmon resonance. Analysis of the association and the dissociation phases of the interaction between the immobilized E. coli human p53 and DO-1 was performed for the full length antibody and the scFv. Expression of the DO-1 scFv in E. coli. (a) an ELISA capture assay was used to measure the binding activity of the puri®ed soluble DO-1 scFv (100 ng/ml) against recombinant human p53 expressed in insect cells (0.4 mg/ml), E. coli (0.6 mg/ ml), or human tumour H1299 cells (black columns). Controls in the white columns represent background signal in the absence of p53. (b) ELISA to determine the ®ne speci®city of DO-1 antibody (2 mg/ml) (white column) and phage-displayed scFv (black column) against dierent biotinylated synthetic peptides containing the human DO-1 epitope (SDLWKL sequence, peptides A and B), or the corresponding region of murine p53 (SGLWKL sequence, peptides C and D). ). These two kinetics parameters result in an association constant Ka almost identical for both antibodies: 3.0610 9 M 71 for the scFv and 3.6610 9 M 71 for the DO-1 antibody. Taken together, these data indicate that the recombinant DO-1 scFv has the same immunological properties as the full length DO-1 antibody, in terms of ®ne speci®city and anity.
DO-1 scFv inhibits the p53-Hdm2 interaction
It has been shown that both the DO-1 antibody and Hdm2 interact with p53 at overlapping binding sites (Picksley et al., 1994; Stephen et al., 1995; Bottger et al., 1996) . DO-1 binds the 20SDLWKL25 sequence and Hdm2 the 18TFSDLWKLL26 sequence. An important question to determine prior to iniating the expression of the scFv in cells was whether the DO-1 recombinant antibody fragment is able to inhibit p53-Hdm2 interaction. This was investigated by surface plasmon resonance measurements where Hdm2 binding to immobilized human p53 was examined before and after pre-incubation with DO-1 scFv or DO-1 full length antibody. Figure 4a illustrates a sensorgram where the presence of the DO-1 scFv (660 nM) prevents the binding of Hdm2 to p53 at least to the same extent as the DO-1 antibody (330 nM). Control experiment shows that an irrelevant antibody (330 nM) has no eect on the Hdm2-p53 interaction ( Figure 4a , curve 3). Bottger and colleagues (1997) have shown that p53 retains its sequence-speci®c DNA binding activity after complex formation with Hdm2. Figure 4b illustrates the results of DO-1 scFv's eects on the Hdm2-p53 interaction as determined by EMSA. A titration of the DO-1 scFv ( Figure 4b , lanes 4 ± 9) leads to the disappearance of Hdm2/p53 complexes and the appearance of scFv/p53 complexes, demonstrating that the recombinant antibody is able to displace Hdm2 from human p53.
DO-1 scFv is a powerful protecting agent of DNA binding activity of p53 at 378C
It is known that the DNA binding activity of p53 is lost following extended incubations at 378C (Hansen et al., 1996) . Further stabilization of p53's DNA binding activity at 378C can be regulated by interaction with heat shock proteins or monoclonal antibodies recognizing N-terminal epitopes on p53 (DO2, DO1, 1801 antibodies). Hansen and colleagues (1996) showed that ecient stabilization only takes place when all subunits of the tetrameric p53 are bound by two bivalent antibodies or four monovalent Fabs. The mechanism of the stabilization event induced by the monoclonal antibodies seems to be mediated by a protection of the wild-type conformation of p53. Gel mobility shift assay: insect-cell produced human p53 (90 nM) was preincubated for 30 min alone (lanes 1 and 3) or with GST-Hdm2 (1300 nM) (lanes 2, 4 ± 9). The puri®ed DO-1 scFv was then added and the incubation continued for 30 min: 1 nM (lane 4), 2 nM (lane 5), 10 nM (lane 6), 30 nM (lane 7), 120 nM (lane 8) and 500 nM (lanes 3 and 9). The white arrow indicates insect cell-produced p53/DNA complexes migration, and the black arrow the DO-1 scFv/p53/DNA complexes position It was of interest to investigate the behaviour of the DO-1 scFv under the same experimental conditions. As described by Hansen and colleagues (1996) , incubation of insect cell-produced p53 at 378C for 60 min leads to the loss of the protein's DNA binding activity (Figure 5a , compare lane 1 and lane 5). When the incubation of p53 at 378C is performed in the presence of the DO-1 antibody, p53 is protected by the N-terminal antibody against heat denaturation and DNA binding activity is observed (Figure 5a , compare lane 8 to lane 5). Figure 5a (compare lanes 6 and 7 to lane 5) demonstrates that p53 is still able to bind DNA when the incubation at 378C is performed in the presence of the DO-1 scFv. In order to quantitatively analyse the protection achieved by the recombinant antibody fragment and by the DO-1 monoclonal antibody, we performed the assay with two dierent concentrations of the monovalent scFv (250 or 500 nM) and with 250 nM of bivalent DO-1 antibody. Protection is expressed as the relative percentage of DNA binding after incubation at 378C compared with the binding at 48C (Figure 5b ). Interestingly, with the same number of paratopes of DO-1 present in the reaction (500 nM for the scFv, 250 nM for the DO-1 full length antibody), the DO-1 scFv is shown to be a more potent stabilizing agent by protecting up to 55+1.5% the DNA binding activity of p53, compared to a 20+5.8% protection for the DO-1 antibody. When the same molarity of both antibodies is tested (250 nM), the scFv is still slightly more powerful than DO-1 full length antibody, by achieving a protection of 35+5.8%. Hansen and colleagues (1996) found that the binding of four monovalent Fabs of the 1801 antibody is able to protect p53 from heat denaturation, but to a lesser extent than the parental 1801 antibody, suggesting that the crosslink which the bivalent 1801 antibody could achieve between monomers of p53 could be important in this phenomenon. Our results with the DO-1 scFv show that the bivalency of N-terminal antibodies is not required to ensure the protection of p53's DNA binding activities at 378C, as the binding of small scFv molecules on the DO-1 epitope of wild-type p53 results in a more powerful protection than the one obtained with the binding of DO-1 full length antibody.
Expression of the DO-1 anti-p53 scFv in the cytoplasm and the nucleus of mammalian cells Foreign proteins expressed in the cytoplasm of eukaryotic cells may be prone to rapid degradation in the reducing environment of the cytoplasm. Several anti-p53 expression vectors were constructed to target the anti-p53 DO-1 scFv either to the cytoplasm or to the nucleus of mammalian cells (Mhashilkar et al., 1995) . To ensure a high level of expression, the coding sequence of all DO-1 anti-p53 scFvs were modi®ed to contain a strong Kozak sequence and an initiating methionine immediately 5' to amino acid one of framework one of the heavy chain. A derivative was constructed that contained, fused in frame with the C- terminus of the VL domain, the entire mouse kappa light chain constant domain (Ck), followed by the Etag peptide, to allow immunodetection (Figure 1c ). This construct was called scFvCk and expressed in E. coli to check its ability to bind to human p53 (data not shown). For nuclear targeting, the scFv and scFvCk were additionally modi®ed to contain the C-terminal SV40 nuclear localization signal TPPKKKRKV which has been shown to direct heterologous proteins into the nucleus (Yoneda et al., 1992) . The two nucleus-targeted scFvs were called respectively scFv-SV40 (Figure 1b) and scFvCk-SV40 (Figure 1d) . The four scFvs constructs were cloned into the pcDNA3 vector, under the control of the cytomegalovirus promoter (CMV).
The ability of the dierent DO-1 scFvs to be expressed in mammalian cells was determined by transient transfection of the p537/7 H1299 cell line or the p53+/+ MCF7 cell line. Transfection with the plasmids encoding the scFvCk or scFvCk-SV40 proteins (pcDNA3-scFvCk and pcDNA3-scFvCk-SV40), resulted in strong cytoplasmic and nuclear staining respectively, showing abundant accumulation of the scFv proteins ( Figure 6 ). It was noteworthy that the¯uorescence intensity observed after transfection with the plasmid expressing the scFv-SV40 protein was weaker than with the scFvCk-SV40 construct, and that the¯uorescence for the cytoplasmic-targeted scFv construct was almost non existant. We performed a Western blot with lysates of H1299 cells transfected with the same amount of each of the four scFv constructs (10 mg of DNA), and probed with the anti-E-Tag antibody. A strongly expressed band was visible for the scFvCk-SV40 and scFvCk proteins (*40 KDa) (Figure 7, lanes 1 and 2) , whereas the expression of the scFv-SV40 protein and in particular the scFv protein (*30 KDa) were weaker (Figure 7 , lanes 4 and 5), con®rming the immunostaining observations. All these data suggest that the construct lacking the Ck domain is rapidly degraded in the cytoplasm of mammalian cells, and that addition of the Ck domain at the Cterminus of the DO-1 scFv dramatically increases the stability of the recombinant antibody in an eukaryotic context. DO-1 scFv inhibits p53-mediated transactivation in H1299 cell line p53 activates the transcription of genes containing the p53 consensus sequence. It has already been described that Hdm2 binding is able to inhibit p53 transactivation function, probably by concealing the transactivation domain of p53 from the TAF proteins (Chen et al., 1993; Oliner et al., 1993) . As DO-1 binds to the same region as Hdm2, we examined whether cotransfection with pcDNA3-scFvCk and pcDNA3-scFvCk-SV40 plasmids would interfere with p53-mediated transcriptional activation. Therefore we transfected p53 null human lung carcinoma H1299 cells with the PG13-PY-Luc reporter construct, containing thirteen RGC sequences upstream of a promoter driving transcription of the ®re¯y luciferase gene . As shown on Figure 8a , co-transfection with the plasmid expressing human wild-type p53 (pcDNA3-human p53) strongly enhanced the expression of the reporter construct (lane 2). As previously described, simultaneous transfection with the pCMV-Neobamhdm2 plasmid inhibits the transcription stimulation activity of p53 (83+5% of inhibition) (Figure 8a Figure 8a, lane 4) . In the absence of p53, cotransfection of either the scFv-Ck or scFvCk-SV40 constructs with the reporter had no signi®cant eect on the background signal observed with the reporter alone (data not shown). To support the conclusion that p53 inactivation results from binding between the human p53 protein and the DO-1 intrabody protein, we performed the same experiment using a plasmid expressing the mouse p53 protein, as this is not recognized by the DO-1 antibody. Our peptide binding studies con®rmed the species speci®city of the DO-1 scFv since it is not able to recognize murine p53 (Figure 2b ). No inhibition of mouse p53-mediated transcription was observed in the presence of pcDNA3-scFvCk-SV40 or pcDNA3-scFvCk (Figure 8b , lanes 4 and 5), demonstrating that the observed inhibition of human p53-mediated transcription is the result of a speci®c protein-protein interaction, and is not a consequence of a generic eect of the intrabody on the cellular transcriptional machinery. Since transfection with the plasmid expressing the Mdm2 protein (pCOC-mdm2X2) is able to eciently inhibit the transcriptional activity of murine p53 in this system (Figure 8b , lane 3), these results provide striking proof of the speci®city of the DO-1 intrabody system.
Discussion
Antibody engineering allows the production of recombinant scFv constructs which combine, in a single polypeptide chain, both the variable light and heavy chain domains of an antibody, covalently joined by an engineered polypeptide linker. The most frequently used linker is the (Gly4Ser)3 sequence, as NMR evidence suggests this linker is a¯exible entity which does not change the structure of the variable domains (Freund et al., 1993) . The production of antibody fragments from E. coli is achieved by the functional expression of soluble, correctly folded, fragments into the periplasmic space of the bacteria, while one of the main diculties is the formation of aggregated insoluble material. The intramolecular disul®de bond within antibody domains appears to be crucial for stability, and most antibody domains do not have sucient free energy of folding to tolerate removal of this stabilizing element. Therefore a competition between folding and aggregation occurs, whose determinants are external factors such as temperature and growth parameters, as well as the primary sequence of the antibody. The bacteriallyexpressed scFv-binding site must be presented in such a way that it accurately represents the ligand binding site of the intact antibody, both with respect to anity for the ligand and ®ne speci®city of the binding site. In many cases, scFvs show less anity than the whole antibody, and these dierences have been attributed to alterations in the folding of the recombinant protein molecule, or to the additive impact on anity measurement of two binding sites versus the presence of a single site, in antibodies and scFvs, respectively.
In this study, we describe the expression of a functional DO-1 scFv in the periplasm of E. coli or at the surface of the ®lamentous phage M13. The (1) or in presence of pcDNA3-human p53 (2), pcDNA3-human p53+pCMV-Neobamhdm2 (3), pcDNA3-human p53+pcDNA3-scFvCk-SV40 (4), pcDNA3-human p53+pcDNA3-scFvCk (5). (b) as (a), but pcDNA3-human p53 is replaced with pcDNA3-mouse p53, and pCMV-Neobam-hdm2 with pCOC-mdm2X2. The data represent the mean of at least three independent experiments where each point was performed in duplicate. The error bars represent the standard error of the mean soluble recombinant antibody was shown to possess the immunological properties of the full length DO-1 antibody, namely the same ®ne speci®ty and high anity. Moreover, we showed in EMSA experiments that the monovalent DO-1 scFv is able to protect the DNA binding activity of p53 from heat denaturation at 378C. Analysis of the data highlights that this protection is better achieved by the binding of a small molecule (scFv) on the N-terminal 20-25 region of p53 than by the full length DO-1 antibody.
Recent advances in antibody engineering have now allowed the genes encoding antibodies to be manipulated so that antigen binding molecules can be expressed intracellularly. The speci®c and high-anity binding properties of antibodies, combined with their ability to be stably expressed in precise intracellular locations inside mammalian cells, has provided a powerful new family of molecules for basic research or gene therapy (for review, see Marasco, 1995) . These intracellular antibodies (intrabodies) can be used to modulate cellular physiology and metabolism by a wide variety of mechanisms: blocking, stabilizing or mimicking protein-protein interaction, modulating enzyme function, or diverting proteins from their usual compartment. Intrabodies can be directed to the relevant cellular compartments by modifying the intrabody genes with N-or C-terminal polypeptide extensions that encode classic intracellular-tracking signals. This approach has been described for dierent antigens, including HIV proteins (Mhashilkar et al., 1995; Maciejewski et al., 1995) , erbB-2 (Beerli et al., 1994; Wright et al., 1997) , EGFR (Jannot et al., 1996) , and p21 ras (Biocca et al., 1993) . In the p53 ®eld, the 421 scFv, recognizing a C-terminal epitope of the protein, has been characterized in vitro, but when expressed in the cytoplasm or the nucleus of COS-1 cells, was non functional and prone to rapid degradation (Jannot and Hynes, 1997) . As discussed, an important determinant of antibody folding is the formation of the intra-chain disul®de bonds in the variable regions, and the reducing environment of the cytosol may therefore lead to a decrease of stability of the scFv (Biocca et al., 1995) . However, despite their reduced state, some scFv have been expressed in the cytoplasm and have demonstrated biological eects (Duan et al., 1994; Mhashilkar et al., 1995) , suggesting that other features, such as the primary sequence of the antibody or the speci®c cellular environment also have to be taken into consideration.
In this study we describe the intracellular expression of a scFv directed against an N-terminal epitope of human p53. The DO-1 scFv has been targeted to the cytoplasm and the nucleus of mammalian cells, and the addition of the Ck domain to the scFv as a scFvCk fusion protein leads to a dramatic increase in the level of intracellular expression. Dierent observations demonstrated that for some scFv the addition of the Ck domain increases the stability of the recombinant antibody in an eukaryotic context (Mhashilkar et al., 1995) , but does not for other scFv (Jannot and Hynes, 1997) , showing once more that each scFv is a particular case.
DO-1 antibody recognizes an N-terminal epitope on human p53 (amino acids 20 ± 25), within this epitope the residues L22 and W23 have been shown to be crucial for the binding of Mdm2, TAFs proteins and CBP protein (Lin et al., 1994; Thut et al., 1995; Lu and Levine, 1995; Gu et al., 1997) . It has been suggested that Mdm2 inhibits p53-dependent transcription by concealing p53's transactivation domain from components of the transcriptional machinery (Oliner et al., 1993) . In this work, we show that both the cytoplasmic scFvCk version and to a less extent the nuclear scFvCk-SV40 version lead to a signi®cant inhibition of the transcriptional activity of human p53 in the H1299 cell line. This observation is the result of a speci®c interaction between human p53 and the recombinant antibody, as no inhibition of mouse p53-mediated transcription is observed under the same experimental conditions. The dierence observed in the inhibitory eect of the scFvCk (50.7%) and the scFvCk-SV40 (23.4%) may re¯ect a dierence of folding of the scFvs in the dierent cellular compartments, or a better accessibility of DO-1 towards its epitope on the p53 protein in the cytoplasm rather than the nucleus. As no trapping of p53 in the cytoplasm by the scFvCk construct is observed in H1299 cells by double immunostaining (data not shown), it is likely that the scFvCk/p53 complex occurs as soon as both proteins are synthesized in the cytoplasm, and p53 may then shuttle the scFv to the nucleus. The observed inhibition of transcription, which may occur by concealing the transactivation domain of p53 to TAFs and/or CBP/p300 protein, could then be achieved by the pre-bound scFvCk. One can imagine that in the nucleus, the scFvCk-SV40 construct would have to compete directly for binding with the components of the cellular transcriptional machinery, and would thus be less eective than the scFvCk construct. Recent work suggests that repression of p53-mediated transcription by Mdm2 could be mediated by a second mechanism involving a direct inhibition of the basal machinery through an interaction with the TFIIE factor (Thut et al., 1997) . In this case, the dierence in the inhibition levels observed between Hdm2 (up to 87%) and the DO-1 scFv (up to 59%) might re¯ect the mimicing of only one of the mechanisms by which Mdm2 inhibits p53's transactivation.
Phosphorylation at the N and C-terminus of p53 may modulate the transactivation function of the protein and this eect may vary between the promoters of the dierent p53 responsive genes (Hecker et al., 1996; Lorhum and Scheidtmann, 1996) . As the binding of DO-1 to p53 is sensitive to phosphorylation (T Hupp and A Bottger, manuscripts in preperation), it would be of interest to determine if DO-1 recognizes a discrete sub-fraction of p53 in the cell, and if the DO-1 scFv's activity towards p53 transactivation varies with dierent promoters.
In our in vitro data, we show that the DO-1 scFv is able to inhibit the binding of Hdm2 to p53; it needs to be determined if the DO-1 scFv is able to prevent the formation of Hdm2/p53 complexes in cells. Recent work suggested that Mdm2 is involved in the rapid degradation of p53 through the ubiquitin-dependent pathway (Haupt et al., 1997; . Other studies suggest that calpain proteolysis of p53 in the cell system may occur, and that this proteolysis can be prevented in vitro by the binding of DO-1 antibody Pariat et al., 1997) . It would be of interest to study how the DO-1 scFv would interfere intracellularly with these dierent mechanisms, in order to elucidate the way in which the rate of turnover of p53 is controlled. The DO-1 intrabody should therefore provide an interesting and original tool to study the regulation of p53 functions driven by the N-terminal region of the protein.
Materials and methods

Engineering of the DO-1 scFv
The DO-1 anti-p53 monoclonal antibody (IgG2ak) and its characteristics have been described previously (Vojtesek et al., 1992; Stephen et al., 1995) . mRNA was prepared from the DO-1 hybridoma cells using the Quickprep Micro mRNA puri®cation kit (Pharmacia Biotech, Uppsala, Sweden), and then used as template to construct a cDNA library in the pSPORT 1 plasmid, according to the SuperScript Plasmid System procedure (Gibco BRL, Gathersburg, MD, USA). The bacterial colonies were replicated on a nylon transfer membrane (Hybond N + , Amersham, Buckinghamshire, UK) and then screened by hybridization (Sambrook et al., 1989 ) using the 5'-GCA TCC TAG AGT CAC CGA-3' oligonucleotide (complementary to the ®rst constant domain of murine IgG2a) and the 5'-GTT GTT CAA GAA GCA CAC G-3' oligonucleotide (complementary to the constant domain of mouse kappa light chains) labelled with g-32 P-ATP (5'-end labelling RPN1 1509 kit, Amersham). The positive clones were sequenced, and primers were designed to PCRamplify the VH and Vk DNA fragments with the Vent DNA polymerase (New Englands Biolabs, Beverly, MA, USA). The VHreverse-SfII primer was 5'-CAT GCC ATG ACT CGC GGC CCA GCC GGC CAT GGC CCA GGT TAC TCT GAA AGA GTC T-3' and the VHforward primer was 5'-GCC AGA GCC ACC TCC GCC TGA ACC GCC TCC ACC TGA AGA GAC TGT GAG AGG GGT GCC-3'. The Vkreverse primer was 5'-TCA GGC GGA GGT GGC TCT GGC GGT GGC GGA TCG GAT GTT TTG ATG ACC CAA ATT CCA CTC TCC-3' and the Vkforward-NotI primer was 5'-GAG TCA TTC TGC GGC CGC CCG TTT CAG CTC CAG CTT GGT CCC AGC-3'. The Vkreverse and the VHforward primers contain overlapping sequences (appear in italics) corresponding to the internal ®fteen amino acid-linker (Gly4Ser)3 of the scFv. The DO-1 scFv was then assembled by overlap extension in a PCR reaction by mixing the VHreverse-S®I primer, the Vkforward-NotI primer, the VH DNA fragment, and the Vk DNA fragment. The ampli®ed scFv fragment (*800 bp) was then S®I and NotI-digested and inserted into the pCANTAB 5 E phagemid vector (Pharmacia). To engineer the scFvCk construct (*1200 bp), the Vkforward-NotI primer was replaced by the Ckforward-NotI primer (5'-GAG TCA TTC TGC GGC CGC ACA CTC ATT CCT GTT GAA GCT CTT-3') which anneals to the 3'-end of the constant domain of mouse kappa light chain sequence.
Bacterial expression of the scFv at the surface of the ®lamentous phage M13
One colony of E. coli TG1 bacteria transformed with the pCANTAB5E-scFv was grown at 308C in 26TY medium, 100 mg/ml ampicillin, 2% glucose (26YT-AG medium) until the the culture reached an OD 600 of 0.5. To the bacterial suspensions, helper phage M13KO7 (Pharmacia) was added to a ®nal concentration of 10 9 pfu/ml and infection was allowed to proceed for 2 h at 378C with shaking. After centrifugation, the bacterial pellets were resuspended in 26YT 100 mg/ml ampicillin 50 mg/ml kanamycin and grown overnight at 378C with shaking.
After centrifugation, supernatants were removed, and the phage suspensions were ®ltered through a 0.45 mM ®lter and stored at 48C.
Bacterial expression of the soluble scFv E. coli HB2151 nonsuppressor strain was transformed by infection with the phage suspension. One positive colony isolated on a SOBAG agar plate 100 mg/ml nalidixic acid was then grown in 26YT-AG medium at 308C until the OD 600 reaches 0.5. This fresh culture was induced in 26 YT 100 mg/ml ampicillin 1 mM IPTG and shaken overnight at room temperature. The periplasmic fraction containing the soluble scFv was prepared by resuspending the bacterial pellet in 0.2 M Tris HCl pH 8, 0.5 mM EDTA, 0.5 M sucrose, and incubating on ice for 45 min. After centrifugation, the supernatant containing the soluble scFv was stored at 7208C.
Puri®cation of the soluble scFv
The soluble DO-1 scFv was immunopurifed from the periplasmic fraction on an anti E-Tag Sepharose column (Pharmacia). Brie¯y, after equilibration of the column at pH 7 with a 0.2 M Na 2 /NaHPO 4 buer, the periplasmic fraction was loaded onto the column. After extensive washes with the phosphate buer, the DO-1 scFv was eluted with 1 M glycine pH 3 buer, and the collected fractions were immediatly equilibrated to pH 7 with 1 M Tris pH 8.2 buer. The dierent fractions were assayed for the presence of the scFv by enzyme linked immunosorbent assay (ELISA) and by silver stained SDS gel (ICN, Irvine, CA, USA). The scFv containing-fractions were pooled and dialyzed overnight against 0.1 M KH 2 PO 4 pH 7.4 buer at 48C. The puri®ed scFv was then aliquoted and stored at 7708C.
Human p53 ELISA
Anti-E tag antibody (Pharmacia), 50 ml, 5 mg/ml in a phosphate-buered saline solution (PBS) was adsorbed onto a 96-well PVC assay plate (Falcon) overnight at 48C. After washing with 0.1% Tween 20 PBS (PBST), the wells were blocked with 100 ml PBST containing 5% w/v low fat milk powder (PBSMT) for 2 h at room temperature (RT). After washing with PBST, puri®ed bacterial soluble scFv (0.2 mg/ml in a volume of 50 ml in PBSMT) was added into each well and incubated for 2 h at 48C. After washes with PBST, human p53 was incubated (50 ml, diluted in PBSMT) fo 2 h at 48C. After washes (PBST), the rabbit anti-p53 serum CM1 was added (50 ml, 1/2000 in PBSMT) and incubated for 2 h at 48C. After washes, detection was performed with a swine horse radish peroxidase(HRP)-conjugated anti-rabbit serum (Dako, Glostrup, Denmark).
Wild type human p53 was expressed and puri®ed from E. coli as described elsewhere (Hupp et al., 1992; Hansen et al., 1996) and tested at a 0.6 mg/ml concentration. Human p53 produced in insect cells was kindly provided by T Hupp and tested at a 0.4 mg/ml concentration. Lysate of H1299 cells transiently transfected with human p53 (Lin and Green, 1989) was prepared as described by Harlow and Lane (1988) .
ELISA with biotinylated synthetic peptides.
The human p53 sequence-based peptides have already been described (Stephen et al., 1995) . The peptide ELISA was performed by coating a 96-well PVC plate with Streptavidin (Vector Labs, Peterborough, UK), 100 ml, 5 mg/ml in PBS overnight at 378C. After washing with PBST, the wells were blocked with PBSMT (200 ml) for 1 h at RT. Biotinylated peptides were then added to the streptavidincoated well (50 ml; 5 mg/ml in PBSMT) for 2 h at RT. After washes, the phages suspension (1/8 in PBSMT) was added in a 50 ml volume, and incubated for 2 h at 48C. After washes with PBS, detection was performed using the HRPconjugated anti-M13 serum (Pharmacia) for 2 h at 48C. Control was performed by replacing the phage suspension by DO-1 antibody (2 mg/ml in PBSMT), and the HRPconjugated anti-phage by a rabbit HRP-conjugated antimouse IgG serum (Dako).
Real-time analysis of the DO-1/p53 interaction Interaction between DO-1 antibody or DO-1 scFv were investigated using BIAcore 2000 technology (Biacore AB, Uppsala, Sweden) (Malmqvist, 1993) . E. coli recombinant human p53 was immobilized at pH 6.2 on a sensor chip surface CM5 previously activated with 100 mM N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride/ 400 mM hydroxysuccinimide (EDC : NHS). The amount of immobilized p53 was 600 pg/mm 2 . Several concentrations of either full length DO-1 antibody or DO-1 scFv were injected at a¯ow rate of 20 ml/min. Dissociation was observed for 400 s in running buer only. Regeneration of the sensor chip was performed using 10 ml of 2 M formic acid. The kinetics parameters of the binding reactions were determined using BIAevaluation 3.0 software (Biacore AB) using the global ®tting method (Karlsson and Falt, 1997) . The dissociation rate (o-rate) constant kd and the association rate constant (on-rate) ka were determined simultaneously. The self-consistency of the kinetic data was checked according to Schuck and Minton (1996) .
For the Hdm2 study, the glutathione S-transferase (GST)-fusion Hdm2 (aa 1 ± 188) protein was described previously (Bottger et al., 1996) . Inhibition of GST-Hdm2 binding to E. coli human p53 was investigated in the same conditions as above, for 260 nM of GST-Hdm2 protein before and after preincubation of DO-1 scFv (660 nM) or DO-1 antibody (330 nM). Control experiment was performed by replacing DO-1 scFv or DO-1 antibody with an irrelevant antiTroponin I antibody (330 nM) (Sano® Diagnostics Pasteur, Montpellier, France).
Electrophoretic mobility shift assay (EMSA)
Human p53 was puri®ed from Sf9 cells as previously described (Hupp and Lane, 1994) . Puri®ed fractions active for DNA-binding (Hupp and Lane, 1995) were used in the following EMSA. Binding conditions are described in detail elsewhere (Hupp et al., 1992) . The DNA binding buer contained 20% (v/v) glycerol, 50 mM KCl, 40 mM HEPES, pH 8, 0.05 mM EDTA, 5 mM DTT, 0.1% Triton X-100, 10 mM MgCl 2 , 1 mg/ml bovine serum albumin. The speci®c p53 consensus sequence (PG) was end-labelled with g-32 P-ATP and used in a 20-fold excess of supercoiled competitor DNA (pBluescript II SK + , Stratagene, Cambridge, UK). Displacement of Hdm2 binding was performed by incubating for 30 min GST-Hdm2 (1300 nM) and insect cells-produced human p53 (90 nM) and then by incubating for 30 min with dierent concentrations of DO-1 scFv. A phosphorimager (Molecular Dynamics) was used for the quanti®cation of radioactive signals.
DO-1 scFv constructs for eukaryotic expression
To PCR amplify the scFv and scFvCk versions, the ExpVHreverse primer (5'-TCC CCG CGG CAC CAT GCA GGT TAC TCT GAA AGA-3') and the ExpETagforward primer (5'-GCT CTA GAG CTT ATT AGG CAC GCG GTT CCA GCG GAT CCG GAT-3') were used. For the scFv-SV40 and the scFvCk-SV40 versions, the ExpVHreverse primer and the ExpSV40forward primer (5'-G CTC TAG AGC GGC CGC TTA CTA AAC CTT ACG TTT CTT CTT TGG AGG AGT TCC ACC TCC GGC ACG CGG TTC CAG CGG ATC-3') were used. The PCR products encoding for the dierent constructs were cloned in the pGEM-T Easy vector (Promega, Madison, WI, USA), then digested by XbaI and EcoRI enzymes before cloning in the eukaryotic expression vector pcDNA3 (Invitrogen, Leek, Netherlands) under the CMV promoter. The four dierent constructs were called pcDNA3-scFv, pcDNA3-scFv-SV40, pcDNA3-scFvCk, and pcDNA3-scFvCk-SV40.
Transient transfections for immuno¯uorescence stainings or
Western blot studies of the eukaryotic expressed scfv constructs Human breast tumour (p53+/+) MCF7 cells and p53 null human lung carcinoma H1299 cells were maintained in Dulbecco's Modi®ed Eagle Medium (DMEM), supplemented with 10% foetal calf serum (FCS) at 378C. Cells were seeded 24 h before transfection to 70 ± 80% con¯uence. Calcium phosphate mediated transfections were performed as previously described (Lin and Green, 1989) . Three mg of each of the plasmids encoding the dierent scFv proteins (pcDNA3-scFv, pcDNA3-scFv-SV40, pcDNA3-scFvCk, or pcDNA3-scFvCk-SV40) or 3 mg of control vector (pcDNA3) were transfected per 2.5 cm dish. Twenty-four hours (H1299 cells) or 48 h (MCF7 cells) post-transfection cells were ®xed on the plastic plate with 50% acetone-50% methanol for 2 min. After ®xation, the cells were washed in PBS, then incubated with the mouse anti E-Tag antibody (1 mg/ml, in DMEM-FCS) for 2 h at RT. After washes with PBS, the cells were incubated with a FITC-conjugated anti-mouse IgG serum (Sigma, St Louis, MO, USA), for 1 h at RT. After washes with PBS,¯uorescent labelled cells were examined under¯uorescent microscope.
To compare the stability of the dierent scFv constructs in H1299 cells, 10 mg of each of the four scFv constructs were transfected into a subcon¯uent 10 cm dish culture. Control was performed by transfection with 10 mg of the pcDNA3 vector. Forty-eight hours after transfection, cell lysates (Harlow and Lane, 1988) were fractionated by 12% SDS ± PAGE and transferred to a nitrocellulose membrane. Blots were stained with the anti-Etag antibody (2 mg/ml) and a HRP-conjugated anti-mouse serum (Dako).
Luciferase assay H1299 cells were seeded at 3610 5 cells per 6 cm plate 24 h prior transfection. Cells were then transfected as above with a total of 7 mg of plasmid and the calcium phospate precipitate was left for 6 h. Each calcium precipitate contains 3 mg PG13-PY-luciferase reporter construct, 10 ng of pcDNA3-human p53 and 3 mg of pcDNA3-scFvCk or 3 mg of pcDNA3-scFvCk-SV40. Control was performed by replacing the plasmids encoding the scFv constructs by 1 mg of hdm2 cloned into the pCMVNeobam vector (Oliner et al., 1992) . The pcDNA3 vector was used in order to maintain a constant amount of CMV promoter in each transfection mixture. Twenty-four hours post-transfection, cells were washed with PBS and lysates made in cell culture lysis buer (Luciferase reporter assay system, Promega). After a 15 min incubation, the cell debris was removed by centrifugation, and luciferase activity was determined in a 20 ml sample by adding 100 ml luciferase assay reagent (Luciferase reporter assay system, Promega), and measuring the light produced with a luminometer (1450 Microbeta plus counter, Wallac). Control experiments were performed by replacing human p53 with 10 ng of pcDNA3-mouse p53 and pCMVNeobam-hdm2 with 1 mg of pCOC-mdm2X2 (encoding the Mdm2 protein, Haupt et al., 1996) .
The PG13-PY ®re¯y luciferase reporter was kindly provided by B Volgestein . The pCMVNeobam-hdm2 and pCOC-mdm2X2 plasmids were a gift from M Oren, and are both under the control of a CMV promoter.
Note added in proof While this work was under revision, microinjection of DO-1 antibody in human ®broblasts was shown to block the activation of the transcriptional function of p53 (Gire and Wynford-Thomas, 1998) , con®rming our luciferase assay data.
